RxDoctor Payments Data

John Collins, MD

Internal Medicine · Sarasota, FLNPI 1578567087

Payments from drug & device makers

$293in general payments, 2019–2025

Across 13 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$155
  • Amgen$38
  • Astellas Pharma US Inc$37
  • Amarin Pharma, Inc.$27
  • AstraZeneca$12
  • Johnson & Johnson$12
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,225,166
Medicare patients
1,217
Services billed
34,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$116,192
EliquisApixaban66$81,599
OzempicSemaglutide57$57,194
JanuviaSitagliptin Phosphate33$46,827
XareltoRivaroxaban28$39,932
Breo ElliptaFluticasone/Vilanterol25$17,138
MyrbetriqMirabegron21$16,651
Janumet XrSitagliptin Phos/Metformin Hcl11$16,202
Rosuvastatin Calcium526$7,028
Atorvastatin Calcium675$5,620
Levothyroxine Sodium432$4,022
Omeprazole337$3,702
Metoprolol Succinate201$3,671
SynthroidLevothyroxine Sodium82$3,356
SymbicortBudesonide/Formoterol Fumarate13$2,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$12$63,02944 claims
Johnson & JohnsonXarelto$12$39,93228 claims
Astellas Pharma US IncMyrbetriq$37$16,65121 claims
AstraZenecaSymbicort$12$2,67113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →